ArticleAIDS and behavior2015
True durability: HIV virologic suppression in an urban clinic and implications for timing of intensive adherence efforts and viral load monitoring.
Article in AIDS and behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Change in Condom Use in Populations Newly Aware of HIV Diagnosis in the United States and Canada: A Systematic Review and Meta-Analysis.AIDS and behavior · 2021Pooled it
- A Longitudinal Analysis of Antiretroviral Adherence Among Young Black Men Who Have Sex With Men.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2017Trial
- Longitudinal assessments of viral rebound among people with HIV in South Carolina: a population-based cohort study.AIDS care · 2025Article
- Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.AIDS and behavior · 2024Article
- Evaluating HIV Viral Rebound Among Persons on Suppressive Antiretroviral Treatment in the Era of "Undetectable Equals Untransmittable (U = U)".Open forum infectious diseases · 2020Article
- Associations between symptom severity and treatment burden in people living with HIV.Journal of advanced nursing · 2020Article
- ART Adherence Among Men Who Have Sex with Men Living with HIV: Key Challenges and Opportunities.Current HIV/AIDS reports · 2020Review
- Annual and durable HIV retention in care and viral suppression among patients of Peter Ho Clinic, 2013-2017.PloS one · 2020Article
- Individual, household, and community level barriers to ART adherence among women in rural Eswatini.PloS one · 2020Article
- A Multi-Site Study of Social Cognitive Factors Related to Adherence Among Youth Living With HIV in the New Era of Antiretroviral Medication.Journal of pediatric psychology · 2019Article
- An Exploration of Syndemic Factors That Influence Engagement in HIV Care Among Black Men.Qualitative health research · 2018Article
- Defining Care Patterns and Outcomes Among Persons Living with HIV in Washington, DC: Linkage of Clinical Cohort and Surveillance Data.JMIR public health and surveillance · 2018Article
- Article
- Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC.AIDS care · 2016Article
- Predictors of Self-Reported Adherence to Antiretroviral Medication in a Multisite Study of Ethnic and Racial Minority HIV-Positive Youth.Journal of pediatric psychology · 2016Article
- HIV Nurse Navigation: Charting the Course to Improve Engagement in Care and HIV Virologic Suppression.Journal of the International Association of Providers of AIDS CareObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although the majority of HIV-infected patients who begin potent antiretroviral therapy should expect long-term virologic suppression, the realities in practice are less certain. Durability of viral suppression was examined to define the best timing of targeted adherence strategies and intensive viral load monitoring in an urban clinic population with multiple challenges to ART adherence. We examined the risk of viral rebound for patients who achieved two consecutive viral loads lower than the lower limit of quantification (LLOQ) within 390 days. For 791 patients with two viral loads below the LLOQ, viral rebound >LLOQ from the first viral load was 36.9 % (95 % CI 32.2-41.6) in the first year, 26.9 % (95 % CI 21.7-32.1) in the year following one year of viral suppression, and 24.6 % (95 % CI 18.4-30.9) in the year following 2 years of viral suppression. However, for patients with CD4 ≥300 cells/µl who had 3-6 years of virologic suppression, the risk of viral rebound was very low. At the population level, the risk of viral rebound in a complex urban clinic population is surprisingly high even out to 3 years. Intensified monitoring and adherence efforts should target this high risk period. Thereafter, confidence in truly durable virologic suppression is improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.